Triage

Reviewer: _____

Technology ID #:	
Inventor(s)/Title(s)/Dept:	
Domain/Asset Class:	

Technology Overview

Overview of technology description, who it is for, how it works, what problem it addresses, stage of development the technology is in. This should be a cliff notes version of the invention disclosure and be a "clear" overview of what CCIV thinks the licensable asset is.

Note: All of the categories below will be assessed a score from 0-3 based on the Scoring Guide provided in Exhibit A.

Mission Alignment

Does the technology improve child health, transform delivery of care and/or align with any of the CCHMC POPT goals (see supplemental document for reference)? If yes, briefly explain.

Score:

Unmet Need

Is there an unmet need? Briefly explain, including the potential clinical impact of the technology. If a diagnostic, is there clinical utility? Briefly explain.

Score:

State of the Art

Specific findings should not be listed here. However, scores should be based upon what is found.
The purpose of this section is to perform a cursory search for publicly available information in the specific technology domain.

**Considerations for Digital, Software, Data, Service, etc.

1. *Does this solution use open source? Would this impact licensing?*
2. *Are there algorithms, user interfaces, or databases being disclosed?*
3. *Will Copyright or Trademark be sought?*
4. *Has there been Documentation or SOPs created for these solutions?*

DISCLAIMER: *The information presented here is not intended to be comprehensive. CCIV does not offer legal advice, and the information presented should not be relied on as such. Any official patentability search, analysis and/or opinion should be conducted by IP counsel, at the request of LM, when appropriate.*

Score:

Market

Overview of the market:

- Market Size (TAM) and Trends:
  - Understand the target market's size, growth potential
  - Patient population size or procedures that make up the market
  - Total Revenue, price/unit or procedure (if applicable, including reimbursement rate if readily available)
- Competitive Landscape Analysis:
  - Identify known companies in the space (utilize the table below to list them)
  - Identify existing solutions and their strengths and weaknesses.

| Company	Product Description	Product Revenue	Point of Contact

- Stakeholder Mapping: Map out key players, including payers, providers, patients, and policymakers
- Regulatory landscape
- **Use Hyperlinks**

Score:

Score & Recommendation:

[Double Click the Scorecard below to open Excel table embedded in the document. The Excel table is protected. Only those cells that should be modified are able to be changed. Enter your score in the "score" column for each criteria, except "Market". The overall "Market" score will be automatically calculated based on each score for market sub-criteria.]

	Criteria	Score	Weight	Total
IMPACT	Mission Alignment	3.00	50%	1.50
	Unmet Need	3.00	50%	1.50
	Impact Score			*3.00*
VALUE	State of the Art	1.00	50%	0.50
	Market	2.67	50%	1.33
	Market Size – Revenue (TAM)	3.00	*N/A*	*N/A*
	Patient Population	2.00		
	# of Direct/Indirect Competitors	3.00		
	Value Score			*1.83*

Summary and Recommendation:

Summary of results and recommendations; leverage SLE here as appropriate. e.g., is there data, a pivot, additional development or validation that could move this tech to "proceed."

This recommendation is based on a triage level assessment of the technology to determine the path forward based on standard scoring criteria.

Optional: If subject matter experts (SMEs) are needed, please list who should be considered:

Name	Expertise	Contact Information

Reviewed & Approved by CCIV Review Committee on [date].

EXHIBIT A – Scoring Guide

CRITERIA		SCORE (0-3)			
		0	1	2	3
IMPACT	Mission/Strategic Alignment	Does NOT align with any of the following:	Aligns with 1 of the following:	Aligns with 2 of the following:	Aligns with All of the following:
		Improves Child Health	Improves Child Health	Improves Child Health	Improves Child Health
		Transforms Delivery of Care	Transforms Delivery of Care	Transforms Delivery of Care	Transforms Delivery of Care
		Aligns with at least 1 POPT Goal	Aligns with at least 1 POPT Goal	Aligns with at least 1 POPT Goal	Aligns with at least 1 POPT Goal
	Unmet Need	Need doesn't exist, is already met by existing products, or there are ≥6 products in Phase 2 or 3 clinical trials addressing the same need and there is no signficant rationale for an additional product.	Need is not met by existing products, but there are ≥4 products in Phase 2 or 3 clinical trials. The proposed product has the potential to provide similar benefits to the current standard of care or those in development (e.g., Me Too Product)	Need is not met by existing products, and there are ≤3 products in Phase 2 or 3 clinical trials. The proposed product has the potential to provide an incremental improvement over the current standard of care or those in development.	Need is not met by existing products, and there are ≤1 product in Phase 2 or 3 clinical trials. The proposed product has the potential to be transformative to the current standard of care or those in development.
VALUE	State of the Art	6 sources of publicly available information in the specific technology domain and/or The technology is likely easily replicable and doesn't appear to have differentiating features based on current information available.	4-6 sources of publicly available information in the specific technology domain and/or The technology has some potential differentiating features but likely can be replicated with moderate effort.	1-3 sources of publicly available information in the specific technology domain and/or The technology has potential differentiating features and is likely difficult to replicate.	Issued patent(s) with commercially relevant claims or 0 sources of publicly available information in the specific technology domain and/or The invention operates in a relatively new or unexplored technological space and is likely extremely difficult or impossible to replicate.
	Market				
	Market Size – Revenue (TAM)	See supplemental table below for ranges specific to each asset type.			
	Patient Population*	<200K	200K-1M	1-2.5M	>2.5M
	# of Direct/Indirect Competitors	>15	11-15	5-10	<5

*For an orphan disease, multiply the patient population by 10 to obtain score.

Supplemental Table

Market Size – Revenue (TAM)	0	1	2	3
Small Molecules	<$50M	$50M-$250M	$250M-$500M	>$500M
Biologics, Cell, Gene Therapy	<$50M	$50M-$250M	$250M-$500M	>$500M
Medical Device	<$25M	$25M-$125M	$125-$250M	>$250M
Diagnostics	<$10M	$10M-$50M	$50-$125M	>$250M
Digital Health & Care Delivery	<$25M	$25M-$100M	$100M-$250M	>$250M